Cargando…

Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy

BACKGROUND: Circulating microRNAs may represent novel markers for cardiovascular diseases. We evaluated whether circulating miRNAs served as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy (HCM). METHODS: Cardiac magnetic resonance imaging with postc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Lu, Ellims, Andris H., Moore, Xiao-lei, White, David A., Taylor, Andrew J., Chin-Dusting, Jaye, Dart, Anthony M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581079/ https://www.ncbi.nlm.nih.gov/pubmed/26404540 http://dx.doi.org/10.1186/s12967-015-0672-0

Ejemplares similares

Associations Between Fibrocytes and Postcontrast Myocardial T(1) Times in Hypertrophic Cardiomyopathy
por: Fang, Lu, et al.
Publicado: (2013)

Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction
por: Ellims, Andris H, et al.
Publicado: (2012)

Diffuse myocardial fibrosis in pediatric hypertrophic cardiomyopathy
por: Hussain, Tarique, et al.
Publicado: (2013)

In vivo diffusion-weighted MRI detection of myocardial fibrosis in hypertrophic cardiomyopathy patients
por: Nguyen, Christopher T, et al.
Publicado: (2015)

Hypertrophic obstructive cardiomyopathy complicated with acute myocardial infarction and diffuse fibrosis: surgery or not?
por: Wang, Yunhong, et al.
Publicado: (2022)

Myocardial fibrosis in desmin-related hypertrophic cardiomyopathy
por: He, Yi, et al.
Publicado: (2010)

Circulating microRNAs as biomarkers for myocardial fibrosis in patients with left ventricular non-compaction cardiomyopathy
por: Szemraj-Rogucka, Zofia M., et al.
Publicado: (2019)

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy
por: Chiti, Enrica, et al.
Publicado: (2021)

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2014)

T(1) mapping for characterization of myocardial fibrosis in hypertrophic cardiomyopathy
por: Liu, Ying, et al.
Publicado: (2016)

Myocardial Fibrosis in Hypertrophic Cardiomyopathy: What Remains to be Proven?
por: Sara, Leonardo
Publicado: (2019)

MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy
por: Huang, Derong, et al.
Publicado: (2020)

Circulating MicroRNAs and myocardial involvement severity in chronic Chagas cardiomyopathy
por: Gómez-Ochoa, Sergio Alejandro, et al.
Publicado: (2022)

Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance
por: Nguyen, Christopher, et al.
Publicado: (2015)

Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications
por: Raman, Betty, et al.
Publicado: (2019)

Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Perspective from Fibroblasts
por: Schlittler, Maja, et al.
Publicado: (2023)

Myocardial fibrosis is not associated with reduced quality of life in patients with dilated or hypertrophic cardiomyopathy
por: Khan, Razi, et al.
Publicado: (2011)

Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2021)

Circulating Biomarkers in Hypertrophic Cardiomyopathy
por: Matthia, Eldon L., et al.
Publicado: (2022)

Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy
por: Kuusisto, Johanna, et al.
Publicado: (2012)

Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure
por: Nguyen, My-Nhan, et al.
Publicado: (2018)

Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy
por: Malahfji, Maan, et al.
Publicado: (2020)

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy
por: Kim, Hyung Yoon, et al.
Publicado: (2020)

Effect of sarcomere and mitochondria-related mutations on myocardial fibrosis in patients with hypertrophic cardiomyopathy
por: Chung, Hyemoon, et al.
Publicado: (2021)

MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2015)

Is There a Potential Therapeutic Role for Caveolin-1 in Fibrosis?
por: Shihata, Waled A., et al.
Publicado: (2017)

Exercise and myocardial injury in hypertrophic cardiomyopathy
por: Cramer, G Etienne, et al.
Publicado: (2020)

Interrelationship of LV mass, focal fibrosis by LGE, and diffuse fibrosis by T1-changes in patients with hypertrophic cardiomyopathy
por: Potluri, Rahul, et al.
Publicado: (2012)

A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction
por: Jaguszewski, Milosz, et al.
Publicado: (2014)

Regional diffuse fibrosis and strain characteristics differ between children with hypertrophic and dilated cardiomyopathy
por: Patel, Jyoti K, et al.
Publicado: (2015)

Sex differences in atrial remodeling and its relationship with myocardial fibrosis in hypertrophic obstructive cardiomyopathy
por: Bi, Xuanye, et al.
Publicado: (2022)

Evaluation of diastolic dysfunction in children with hypertrophic cardiomyopathy and its relationship with development of myocardial fibrosis
por: Deraz, Salem Elsayed, et al.
Publicado: (2023)

Diffuse Myocardial Fibrosis detected by Multi-slice T(1) Mapping using Slice Interleaved T(1) (STONE) Sequence in Patients with Hypertrophic Cardiomyopathy
por: Kato, Shingo, et al.
Publicado: (2016)

Stress cardiomyopathy in a patient with hypertrophic cardiomyopathy and myocardial bridging
por: Benavides, Miguel, et al.
Publicado: (2017)

Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy
por: Ho, Jennifer E, et al.
Publicado: (2017)

Circulating cardiac MicroRNAs safeguard against dilated cardiomyopathy
por: Cheng, Xiaolei, et al.
Publicado: (2023)

Biomarker validation of cardiac magnetic resonance analysis of regional myocardial fibrosis in ischaemic heart disease
por: Costello, Benedict T, et al.
Publicado: (2016)

Dual apical hypertrophic cardiomyopathy and endomyocardial fibrosis pathology
por: Martini, Chiara, et al.
Publicado: (2023)

Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy
por: Rixon, Chloe, et al.
Publicado: (2022)

An Unusual Presentation of a Myocardial Crypt in Hypertrophic Cardiomyopathy
por: van de Sande, Danny A. J. P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pdrsuiktr9j5jm54fn3oc5o3dj